NeuroOne Reports Q4 Revenue Growth and Secures $4.5 Million Purchase Order

EDEN PRAIRIE, Minn., Oct. 05, 2026 /CourierPR/ -- NeuroOne Medical Technologies Corporation, a company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, reported preliminary product revenue figures for its fourth fiscal quarter and full fiscal year ended September 30, 2026. The company saw a significant increase in revenue, with product sales for the quarter reaching $3.8 million, marking a 38.4% year-over-year growth compared to the $2.7 million reported in the same period of fiscal 2025. For the full fiscal year 2026, NeuroOne achieved a product revenue of $10.5 million, a 15.6% increase from the $9.2 million to $10.5 million revenue guidance range it had set for itself.

The company's momentum continued to grow, as it secured a $4.5 million product purchase order in September 2026, the largest in its history. Approximately $1.0 million of this order was shipped in September, with the remaining $3.6 million expected to be shipped during the first quarter of fiscal 2027 and into the second quarter of the same fiscal year. Following the receipt of this order, total open purchase orders for shipments through the first quarter of fiscal 2027 increased to $5.4 million as of September 30, 2026. This significant order provides greater visibility into anticipated product shipments, cash flow, and revenue opportunities as the company enters fiscal 2027.

Complete financial results for the fourth quarter and full fiscal year 2026 are expected to be announced in December 2026, in conjunction with the filing of the company's Annual Report on Form 10-K with the Securities and Exchange Commission. The company notes that the selected unaudited financial results included in this press release are preliminary and subject to the completion of year-end accounting and audit procedures. The release also includes forward-looking statements, which are subject to risks and uncertainties, as detailed in the press release.

The company's product families include the Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. NeuroOne is engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.

The press release concludes by emphasizing the company's commitment to innovation and growth, highlighting the significance of the $4.5 million purchase order and the anticipated growth drivers for the upcoming fiscal year.